Clinical trials
Phase 1/2 Recurrence trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Completed | 13 |
| Terminated | 9 |
| Active, not recruiting | 7 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Princess Maxima Center for Pediatric Oncology | 3 |
| AbbVie | 2 |
| Celgene | 2 |
| Hoffmann-La Roche | 2 |
| Incyte Corporation | 2 |
| Kite, A Gilead Company | 2 |
| Advesya SAS | 1 |
| Amgen | 1 |
| Amgen Research (Munich) GmbH | 1 |
| Aprea Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 47 |
| Leukemia, Myeloid, Acute | 10 |
| Multiple Myeloma | 8 |
| Neoplasms | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Leukemia | 7 |
| Lymphoma | 5 |
| Lymphoma, B-Cell | 5 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Lymphoma, Mantle-Cell | 4 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.